These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 21263194)

  • 1. Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.
    Roher AE; Maarouf CL; Daugs ID; Kokjohn TA; Hunter JM; Sabbagh MN; Beach TG
    J Alzheimers Dis; 2011; 24(2):315-25. PubMed ID: 21263194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy.
    Roher AE; Cribbs DH; Kim RC; Maarouf CL; Whiteside CM; Kokjohn TA; Daugs ID; Head E; Liebsack C; Serrano G; Belden C; Sabbagh MN; Beach TG
    PLoS One; 2013; 8(3):e59735. PubMed ID: 23555764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer's disease.
    Zampar S; Klafki HW; Sritharen K; Bayer TA; Wiltfang J; Rostagno A; Ghiso J; Miles LA; Wirths O
    Neuropathol Appl Neurobiol; 2020 Dec; 46(7):673-685. PubMed ID: 32497293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry.
    Carlred L; Michno W; Kaya I; Sjövall P; Syvänen S; Hanrieder J
    J Neurochem; 2016 Aug; 138(3):469-78. PubMed ID: 27115712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry.
    Portelius E; Lashley T; Westerlund A; Persson R; Fox NC; Blennow K; Revesz T; Zetterberg H
    Neurodegener Dis; 2015; 15(1):50-7. PubMed ID: 25591542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-β-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Paris F; Santamato A; D'Onofrio G; Logroscino G; Pilotto A; Solfrizzi V
    Curr Alzheimer Res; 2011 Dec; 8(8):808-17. PubMed ID: 21592055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
    Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
    Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease.
    Terai K; Iwai A; Kawabata S; Tasaki Y; Watanabe T; Miyata K; Yamaguchi T
    Neuroscience; 2001; 104(2):299-310. PubMed ID: 11377835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
    Güntert A; Döbeli H; Bohrmann B
    Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-truncated Aβ
    Wirths O; Walter S; Kraus I; Klafki HW; Stazi M; Oberstein TJ; Ghiso J; Wiltfang J; Bayer TA; Weggen S
    Alzheimers Res Ther; 2017 Oct; 9(1):80. PubMed ID: 28978359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation.
    Miles LA; Crespi GA; Doughty L; Parker MW
    Sci Rep; 2013; 3():1302. PubMed ID: 23416764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
    Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; Barakos J; Okello AA; Rodriguez Martinez de Liano S; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M
    Lancet Neurol; 2010 Apr; 9(4):363-72. PubMed ID: 20189881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer's Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry.
    Kaya I; Brinet D; Michno W; Syvänen S; Sehlin D; Zetterberg H; Blennow K; Hanrieder J
    ACS Chem Neurosci; 2017 Feb; 8(2):347-355. PubMed ID: 27984697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TgCRND8 amyloid precursor protein transgenic mice exhibit an altered gamma-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation.
    Van Vickle GD; Esh CL; Kalback WM; Patton RL; Luehrs DC; Kokjohn TA; Fifield FG; Fraser PE; Westaway D; McLaurin J; Lopez J; Brune D; Newel AJ; Poston M; Beach TG; Roher AE
    Biochemistry; 2007 Sep; 46(36):10317-27. PubMed ID: 17705508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
    Cribbs DH
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-based chimeric HPV-virus-like particles bearing amyloid-β epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer's disease brains.
    Gonzalez-Castro R; Acero Galindo G; García Salcedo Y; Uribe Campero L; Vazquez Perez V; Carrillo-Tripp M; Gevorkian G; Gomez Lim MA
    Inflammopharmacology; 2018 Jun; 26(3):817-827. PubMed ID: 29094307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.